Intervacc Ab · OMXSTO:IVACC
Intervacc Ab — Q4 2022 Earnings Presentation
25 slides from Intervacc Ab's earnings presentation, February 2023
Slide 1: Intervacc
INTERVACC Andreas Andersson Dr Andrew Waller February 2023 Chief Scientific Officer Chief Executive Officer
Slide 2: Important notice
Important notice IMPORTANT INFORMATION THIS PRESENTATION WHICH SHOULD BE UNDERSTOOD TO INCLUDE THESE SLIDES, THEIR CONTENTS OR ANY PART OF THEM, AND ANY ORAL PRESENTATION OR ELABORATION OR ANY QUESTION AND ANSWER SESSION IN RELATION THERETO (THE “PRESENTATION”) IS STRICTLY CONFIDENTIAL AND BEING PRO
Slide 3: Q4 update
Q4 update Oct - Dec Jan - Dec ▪ During the quarter Strangvac was launched in key European markets 2022 2021 2022 2021 Germany, France, Austria, Belgium, the Netherlands, Luxemburg, Ireland, Poland and Italy Net sales 3,884 1,068 9,684 5,241 ▪ Intervacc and the Swedish University of Agricultural Scie
Slide 4: Intervacc – A fully integrated animal health vaccine company
Intervacc – A fully integrated animal health vaccine company Developing and commercializing modern, safe and effective vaccines for animals, focused on infectious 1 diseases caused by streptococci and staphylococci, based on a technology platform using recombinant fusion proteins. Potential to reduc
Slide 5: Strong current momentum based on key achievements
Strong current momentum based on key achievements ✓ Strangvac® granted marketing authorization from EMA and VMD Developing modern, safe and effective vaccines for animals Our ✓ Technology platform based on recombinant fusion ✓ Strangvac® European distribution agreement signed expertise proteins with
Slide 6: Developing modern, safe and effective vaccines for animals, based on our technology platform
Developing modern, safe and effective vaccines for animals, based on our technology platform with recombinant fusion proteins Antigens manufactured in large scale Technology platform enables strong safety ✓ profile Fused DNA fragment Surface protein Suitable for large scale manufacturing (high ✓ ant
Slide 7: Promising pipeline targets significant unmet needs in several animal species
Promising pipeline targets significant unmet needs in several animal species VACCINE DESIGN AND PROOF OF CONCEPT OPTIMISED MANUFACTURING REGULATORY PHASE SAFETY STUDIES STUDIES IN TARGET ANIMAL AND CLINICAL TRIALS AND LAUNCH TO (PHASE I) (PHASE II) (PHASE III) MARKET Strangvac® for Strangles Based o
Slide 8: Strangvac targets the severe, common and highly contagious disease Strangles
Strangvac® targets the severe, common and highly contagious disease Strangles DESCRIPTION OF STRANGLES ANATOMY OF A HEALTHY HORSE AND INFECTED HORSES WITH NASAL DISCHARGE AND RUPTURED ABSCESSES A severe and fatal disease. Up to 100% morbidity and 10% mortality The most common vaccine preventable inf
Slide 9: Our lead product Strangvac – a vaccine against equine strangles, is approved in Europe
Our lead product Strangvac® – a vaccine against equine strangles, is approved in Europe (EMA & VMD) STRANGVAC® IS A MULTICOMPONENT FUSION PROTEIN SUBUNIT VACCINE No live agent Intramuscular administration Strangvac conferred significant levels of protection after two doses. Up to 94% efficacy in cli
Slide 10: Strangvac targets a global market
Strangvac® targets a global market STRANGVAC® ADDRESSES A GLOBAL POPULATION OF 60 MILLION HORSES Sales start 2022 Vaccines are disease ✓ Sweden (March) preventing and target a large ✓ Denmark (June) proportion of the market rima ry marke ✓ The UK (August) ry marke rima P t ✓ Germany (October) P t No
Slide 11: Status update on Strangvac US regulatory process
Status update on Strangvac® US regulatory process THE USDA PROCESS CAN BE ILLUSTRATED AS THREE STAGES1) STAGE I STAGE II STAGE III ✓ Detailing qualifications for each key ▪ Potency, Efficacy & Safety validation ▪ Labeling and production (including facility approval employee and liaison after local i
Slide 12: Clear potential for increased adoption of Strangvac
Clear potential for increased adoption of Strangvac® STRANGLES OUTBREAKS ARE MUCH MORE COMMON THAN EQUINE INFLUENZA… … DUE TO HIGHER RATES OF VACCINATION Average number of yearly outbreaks in Sweden, 2016-20211) Estimated EIV vaccination rate 72 30-70% Common: 1 or 2 outbreaks per week in Sweden 7 A
Slide 13: Manufacturing for global demand with world class CDMOs
Manufacturing for global demand with world class CDMOs Production of Strangvac Antigens are produced in a process with sufficient yield for millions of vaccine doses Vaccine doses are formulated by mixing the antigens with adjuvant The vaccine doses are filled into vials that are labelled, packaged
Slide 14: Strangvac anticipated global growth path
Strangvac® anticipated global growth path BASE OF S-CURVE AND FINANCIAL INFORMATION FROM JAN 2023 Horses in Strangvac vaccination program as percentage of “peak” Horses in Strangvac vaccination program as percentage of total population 100% 100% 80% 80% Long-term target: annual 60% sales of SEK >1 b
Slide 15: Strangvac – progressing up the S-curve
Strangvac® – progressing up the S-curve STRATEGY – IT TAKES TIME TO BUILD A MARKET AND CONVERT ACTIVITIES INTO SALES OUR MARKETING AND SALES ACTIVITIES FIT INTO THE STRATEGY Building the market, creating demand Building brand image, encouraging use • Increase awareness of Strangles • A modern and ea
Slide 16: Strangvac getting horses into the vaccination program – tipping points
Strangvac® getting horses into the vaccination program – tipping points STRANGLES OUTBREAKS DRIVE AWARENESS AND THE CALL TO ACTION EXPERIENCE FROM THE FIELD – ADOPTION AND SUPPORT IS GROWING Strangles outbreaks are common and occur throughout the year ▪ Stables requiring vaccination against strangle
Slide 17: Great responses to awareness campaigns and positive KOL feedback
Great responses to awareness campaigns and positive KOL feedback POSITIVE MESSAGES FROM KEY OPINION LEADERS PROMISING RESPONSE FROM LAUNCH CAMPAIGNS I believe a strangles vaccine can make a big difference. Instead of “” having one to two outbreaks per week in Sweden, maybe we could have one or two p
Slide 18: Distribution partner Dechra highlighting Strangvac
Distribution partner Dechra highlighting Strangvac® Positive feedback from launch Recent Joint activates • Irish Equine Veterinary Association (IEVA) Conference in Ireland • London Vet Show • Dutch Equine Conference • Jumping Amsterdam Vet. Congress and FEEVA core meeting 18 Q4 - Investor Presentati
Slide 19: Feedback from the field since Strangvac vaccinations commenced
Feedback from the field since Strangvac® vaccinations commenced ▪ Over 100 horses that were not ▪ 15 Icelandic horses had been associated ▪ In a recent, ongoing, outbreak in Austria, a vaccinated with Strangvac® developed with an outbreak, but those that had not large number of horses have been infe
Slide 20: Promising pipeline targets significant unmet needs in several animal species
Promising pipeline targets significant unmet needs in several animal species VACCINE DESIGN AND SAFETY PROOF OF CONCEPT STUDIES IN OPTIMISED MANUFACTURING AND REGULATORY PHASE AND STUDIES (PHASE I) TARGET ANIMAL (PHASE II) CLINICAL TRIALS (PHASE III) LAUNCH TO MARKET Strangvac® for Strangles Ongoing
Slide 21: Animal vaccine pipeline S. suis causing sepsis
Animal vaccine pipeline S. suis causing sepsis INV274 FOR STREPTOCOCCUS SUIS INFECTION ▪ Streptococcus suis infection in piglets is one of the most common bacterial causes of fatal infection in piglets leading to big losses in production – Global pig population estimated to approx. 1 billion pigs –
Slide 22: S. suis vaccine Total Accessible Market
S. suis vaccine Total Accessible Market KEY MARKET DYNAMICS MARKET PROJECTIONS AND TRENDS Tentative vaccination schedule is based on USDA projections of Sow inventory (millions) vaccinating breeding sows with a primary course 39,5 40,0 2021 of two doses and revaccination/booster dose 2022 before eac
Slide 23: Animal vaccine pipeline S. aureus causing mastitis
Animal vaccine pipeline S. aureus causing mastitis INV412 FOR STAPHYLOCOCCUS AUREUS MASTITIS ▪ Mastitis, caused by Staphylococcus aureus infections, is a common problem that causes significant production losses in the dairy industry – Global dairy cow population estimated to approx. 250 million cows
Slide 24: Our strategic priorities
Our strategic priorities Near-to-medium term ➢ Commercialization of Strangvac® Strangvac® ➢ US regulatory process ➢ Oceania regulatory process Pipeline projects ➢ Continued development of vaccines against S. suis and S. aureus 24 Q4 - Investor Presentation - General information about the Company int
Slide 25: Q&A
Q&A 25 Q4 - Investor Presentation - General information about the Company intended only for the shareholders and potential investors